Sign up for free insights newsletter
EL

Elite Pharma Inc

ELTPUnited States

Need professional-grade analysis? Visit stockanalysis.com

$0.38
-0.55%
End of day
Market Cap

$409.26M

P/E Ratio

N/A

Employees

N/A

Dividend Yield

N/A

Price Chart

Risk-Adjusted Performance

Ratio1W1M3M6M1Y5YScore
Sortino-1.45-1.57-0.39-1.05
Calmar-2.17-1.36-0.33-1.13
Sharpe-0.89-1.10-0.25-0.69
Omega0.790.731.010.86
Martin-4.08-2.31-0.63-2.05
Ulcer14.9328.0927.4724.54

Elite Pharma Inc (ELTP) Price Performance

Elite Pharma Inc (ELTP) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $0.38, down 0.55% from the previous close.

Over the past year, ELTP has traded between a low of $0.32 and a high of $0.77. The stock has lost 19.6% over this period. It is currently 50.9% below its 52-week high.

Elite Pharma Inc has a market capitalization of $409.26M.

About Elite Pharma Inc

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates through Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals segments. It owns, licenses, manufactures, and sales of generic, oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. In addition, the company provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with sequestered Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. Additionally, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Company Info

Exchange
United States
Currency
USD

Financial Metrics

Revenue (TTM)
$140.12M
EBITDA
$53.27M
Profit Margin
30.98%
EPS (TTM)
0.04
Book Value
0.07

Technical Indicators

52 Week High
$0.82
52 Week Low
$0.27
50 Day MA
$0.43
200 Day MA
$0.55
Beta
0.36

Valuation

Trailing P/E
9.50
Forward P/E
N/A
Price/Sales
2.92
Price/Book
5.07
Enterprise Value
$394.40M